A healthy life sciences eco-system^1
is an environment where all stakeholders, patients, researchers,
governments, the civil society and manufacturers, work together to support the sustainable development and provision of innovative solutions that address unmet health needs. To build a stronger eco-system, governments could prioritise policy initiatives such as: facilitating the commercialisation of academic research; encouraging clinical research; accelerating the adoption and diffusion of new innovative medicines; and promoting the local market as a place to invest and deliver life sciences innovation [1].
Historically, the development of medicines has been primarily undertaken in,
and for the benefit of, high income countries. Over the last 20 years, this has started to change, partly as a result of the market opportunity increasing in middle-income countries (MICs) and low-income countries (LICs)
and partly because governments in these countries have recognised the importance of encouraging innovative industries, resulting in a greater priority given to addressing diseases highly prevalent in MICs and LICs.
In this article, we draw on our experience to develop lessons on how to establish a sustainable life sciences eco-system in MICs and LICs. We highlight the importance of different types of government policy (industrial policy, the regulatory framework, intellectual property, and improving access to medicines) and how success requires different stakeholders (public and private, international and national) to work together.
PupplawarG. et al., Conducting clinical trials in emerging markets of sub-Saharan Africa: Review of guidelines and resources for foreign sponsors, Journal of Clinical Trials7 (2014).
Berger et al., Strengthening pharmaceutical innovation in Africa. Council on Health Research for Development and New Partnership for Africa's Development, 2010.
Tidd et al., Managing Innovation: Integrating Technological, in: Market and Organizational Change3rd Ed, John Wiley & Sons, England, 2005.
13.
KillicB., Boosting Pharmaceutical Innovation in the Post-Trips Era: The Real Life Lessons for the Developing World, Queen Mary University of London, 2011.
14.
PorterM., Clusters and the New Economics of Competition, Harvard Business Review (1998).
15.
MuroM. and KatzB., The New “Cluster Moment”: How Regional Innovation Clusters Can Foster the Next Economy, Metropolitan Policy Program at Brookings, 2010.
16.
KiriyamaN., Trade and Innovation: Pharmaceuticals, OECD Trade Policy Working Papers, No. 113, OECD Publishing, 2011.
CockburnI., Pharmaceuticals, in Innovation in Global Industries: US Firms Competing in a New World (Collected Studies), in J.T. Macher and D.C. Mowery, eds, National Academies Press, 2008, pp. 207-230.
22.
AbrolD. et al., Globalization of the Indian Pharmaceutical Industry: Implications for Innovation, International Journal of Institutions and Economies3 (2011), 327-365.
23.
RahmanS. et al., Physician participation in clinical research and trials: issues and approaches, Dovepress2 (2011).
24.
van GijnW. et al., Quality assurance in rectal cancer treatment in the Netherlands: A catch up compared to colon cancer treatment, European Journal of Surgical Oncology4 (2010), 340-344.
GalvaoJ. et al., How the pandemic shapes the public health response - the case of HIV/AIDS in Brazil, in: Public Health Aspects of HIV/AIDS in Low and Middle Income Countries, D. Celentano and C. Beyrer, eds, Springer, New York, 2008, pp. 135-150.
